News
-
-
-
COMMUNIQUÉ DE PRESSE
Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health
Accord Healthcare launches Osvyrti and Jubereq, biosimilar denosumab products for bone health, expanding patient access to cost-effective medicines. Approved by EMA, aiming to address osteoporosis burden